Transaction in Own Shares

RNS Number : 0078B
Oakley Capital Investments Limited
02 October 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS OR IN OR INTO  THE UNITED STATESCANADAAUSTRALIA, THE REPUBLIC OF SOUTH AFRICAJAPAN OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

 

2   October 2020

Oakley Capital Investments Limited

 

Transaction in own Shares

 

The Company announces that, further to its announcement on 2 October 2020, it has purchased 3.053 million ordinary shares of £0.01 each ("Ordinary Shares") at a price of 252.5 pence per share for cancellation.

 

Following this transaction, there are 187,506,936 Ordinary Shares in issue and admitted to trading on the Specialist Fund Segment of the London Stock Exchange's main market, none of which are held in treasury.

 

The total number of voting rights in the Company is 187,506,936. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oakley Capital Investments Limited under the FCA's Disclosure and Transparency Rules.

- ends -

 

For further information please contact:

 

Oakley Capital Limited

+44 20 7766 6900

Steven Tredget, Investor Relations

 

Greenbrook Communications Limited

+44 20 7952 2000

Alex Jones / Gina Bell / James Williams

 

Liberum Capital Limited (Financial Adviser & Broker)

+44 20 3100 2000

Gillian Martin / Owen Matthews

 

Notes:

LEI Number: 213800KW6MZUK12CQ815

About Oakley Capital Investments Limited ("OCI")

OCI is a  Specialist Fund Segment ("SFS")  traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds 2 .

A video introduction to OCI is available at  https://oakleycapitalinvestments.com/videos/

Oakley Capital, the Investment Adviser

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.

The Oakley Funds

Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV and Oakley Capital Origin Fund are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement.

Important information

Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore, the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules.

The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFVEILLFIII
UK 100